Transcode Therapeutics (RNAZ) Enterprise Value (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Enterprise Value came in at -$12.8 million in Q1 2026, down 10.34% YoY from -$14.3 million in Q1 2025, and up 28.14% on a QoQ basis from -$17.8 million in Q4 2025.
Transcode Therapeutics (RNAZ) Enterprise Value (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Enterprise Value data on file, last reported at -$12.8 million in Q1 2026.
- Quarterly Enterprise Value fell 10.34% year-over-year to -$12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.8 million (down 10.34% YoY) and the FY2025 annual result came in at -$17.8 million, down 206.54% from the prior year.
- Enterprise Value improved to -$12.8 million in Q1 2026, from -$17.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.6 million in Q1 2023 to a low of -$17.8 million in Q4 2025.
- A 5-year average of -$7.5 million and a median of -$5.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 16801.22% — and 2023, when it soared 90.46%.
- Tracing RNAZ's Enterprise Value over 5 years: stood at -$5.0 million in 2022, then jumped by 44.4% to -$2.8 million in 2023, then tumbled by 109.97% to -$5.8 million in 2024, then sank by 206.54% to -$17.8 million in 2025, then climbed by 28.14% to -$12.8 million in 2026.
- The last three Enterprise Value figures came in at -$12.8 million (Q1 2026), -$17.8 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 2.12 Bn |
| 10 | Transcode Therapeutics | 2.80 Mn | 2.80 Mn | - | -8.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.80 Mn |
| Dec 31, 2025 | -17.81 Mn |
| Sep 30, 2025 | -2.80 Mn |
| Jun 30, 2025 | -7.37 Mn |
| Mar 31, 2025 | -11.60 Mn |
| Dec 31, 2024 | -5.81 Mn |
| Sep 30, 2024 | -1.88 Mn |
| Jun 30, 2024 | -3.40 Mn |
| Mar 31, 2024 | -4.90 Mn |
| Dec 31, 2023 | -2.77 Mn |
| Sep 30, 2023 | -7.50 Mn |
| Jun 30, 2023 | -3.57 Mn |
| Mar 31, 2023 | -1.61 Mn |
| Dec 31, 2022 | -4.98 Mn |
| Sep 30, 2022 | -8.80 Mn |
| Jun 30, 2022 | -13.45 Mn |
| Mar 31, 2022 | -16.86 Mn |
| Dec 31, 2021 | -20.84 Mn |
| Sep 30, 2021 | -22.51 Mn |
| Jun 30, 2021 | -79,567.00 |